Immune Pharmaceuticals Inc (IMNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Immune Pharmaceuticals Inc (IMNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH368144D
  • |
  • Pages: 64
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Immune Pharmaceuticals Inc (Immune Pharma) formerly EpiCept Corporation, is a pharmaceutical company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and cancer. The company's bertilimumab is under clinical development for moderate to severe ulcerative colitis, crohn's disease and bullous pemphigoid. It also offers nanomabs, which is an antibody nanoparticle conjugate technology platform for the targeted delivery of chemotherapeutics. Immune Pharma's crolibulin is a small molecule vascular disrupting agent that is used for the treatment of solid tumors. The company develops drugs in the areas of immuno oncology, nano-dermatology and neuropathic pain. It has research and development facility in Herzliya-Pituach, Israel. Immune Pharma is headquartered in New York, the US.

Immune Pharmaceuticals Inc (IMNP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Immune Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Immune Pharma Acquires Rights to AMB8LK from MabLife 14

Venture Financing 15

Immune Pharma Raises US$2 Million In Venture Financing 15

Partnerships 15

Immune Pharma Enters into Agreement with STC Biologics 15

Immune Pharma Plans to Partner with Hebrew University of Jerusalem 16

Immune Pharma Enters Into Co-Development Agreement With Yeda Research 16

Licensing Agreements 17

Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma 17

SATT Sud Est Enters into Licensing Agreement with Immune Pharma 18

Maxim Pharma Enters into Licensing Agreement with Immune Pharma 19

Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma 20

Immune Pharma Enters into Licensing Agreement with BioNanoSim 21

Immune Pharma Enters into Licensing Agreement with Atlante Biotech 21

Immune Pharma Enters into Licensing Agreement with Yissum 22

Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 23

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 24

iCo Therapeutics Exercises Option Licensing Agreement With Immune Pharma For Bertilimumab 25

Equity Offering 26

Immune Pharma to Spin-off its Cytovia 26

Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares 27

Immune Pharma Completes Spin Off of Pain and Neurology Business 28

Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares 29

Immune Pharma to Raise USD2 Million in Share Purchase Plan 29

Immune Pharma to Raise USD1 Million in Private Placement of Shares 30

Immune Pharma to Raise up to USD2.2 Million in Private Placement of Shares 31

Immune Pharma to Raise up to USD1.5 Million in Private Placement of Shares 33

Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock 34

Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million 35

Immune Pharma Raises USD1 Million in Private Placement of Units 36

Immune Pharma Announces Private Placement Of Securities For US$11.7 Million 37

Debt Offering 38

Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes 38

Acquisition 38

Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction 38

Immune Pharmaceuticals Inc-Key Competitors 41

Key Employees 42

Locations And Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Recent Developments 44

Strategy And Business Planning 44

Jan 12, 2016: Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan 44

Financial Announcements 45

May 16, 2016: Immune Pharmaceuticals Provides Business and R&D Update and Announces First Quarter 2016 Financial Results 45

Mar 30, 2016: Immune Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Full Year 2015 Financial Results 46

Corporate Communications 48

Mar 13, 2017: Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement 48

Jan 27, 2017: Immune Pharmaceuticals Appoints New Chairman of the Board of Directors 49

Oct 17, 2016: Immune Pharmaceuticals Announces Formation of Management Team for Maxim Pharmaceuticals, its Pain and Neurology Subsidiary 50

Feb 25, 2016: Immune Pharmaceuticals Names Dr. Jeff Paley to its Board of Directors 51

Feb 03, 2016: Immune Pharmaceuticals Names John Neczesny to its Board of Directors 52

Government and Public Interest 53

Apr 24, 2017: Immune Pharmaceuticals Announces Corporate Restructuring 53

Product News 54

11/22/2016: Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016 54

06/20/2016: New Data shows that Ceplene Enhances Response to anti PD-1 and anti-PD-L1 Immune Checkpoint Inhibitors in Lymphoma and Solid Tumor Models 55

04/19/2016: New Biomarker Data To Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene and Low-dose IL-2 Immunotherapy, Including Those Over 60 Years of Age 56

03/17/2016: New Data on Ceplene Cancer Immunotherapy to be Presented at the 2016 AACR Annual Meeting 57

02/17/2017: Immune Pharmaceuticals Announces the launch of REMAIN, an international Overall Survival study with Ceplene and low dose Proleukin in REmission MAINtenance in Acute Myeloid Leukemia 58

01/17/2017: Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI 59

Clinical Trials 60

Oct 27, 2016: Immune Pharmaceuticals Receives FDA Guidance for Phase III Pivotal Trial of its AML Therapy Ceplene In Combination with Low Dose IL-2 60

Jun 28, 2016: New Data Suggests Improved Tumor Response For The Combination of AZIXA and Immune Checkpoint Inhibitors in The Treatment of Cancer 61

Mar 22, 2016: Immune Pharmaceuticals Announces Publication of Preclinical Data in Support of Its Bispecific Antibody Platform in The Journal of Immunology 62

Other Significant Developments 63

Jan 12, 2016: Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan 63

Appendix 64

Methodology 64

About GlobalData 64

Contact Us 64

Disclaimer 64

List of Figures

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Immune Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Immune Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Immune Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

Immune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Immune Pharma Acquires Rights to AMB8LK from MabLife 14

Immune Pharma Raises US$2 Million In Venture Financing 15

Immune Pharma Enters into Agreement with STC Biologics 15

Immune Pharma Plans to Partner with Hebrew University of Jerusalem 16

Immune Pharma Enters Into Co-Development Agreement With Yeda Research 16

Immune Pharmaceuticals Enters into Licensing Agreement with Pint Pharma 17

SATT Sud Est Enters into Licensing Agreement with Immune Pharma 18

Maxim Pharma Enters into Licensing Agreement with Immune Pharma 19

Novel Pain Therapeutics Amends Option for Licensing Agreement with Immune Pharma 20

Immune Pharma Enters into Licensing Agreement with BioNanoSim 21

Immune Pharma Enters into Licensing Agreement with Atlante Biotech 21

Immune Pharma Enters into Licensing Agreement with Yissum 22

Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 23

Lonza Sales Enters into Licensing Agreement with Immune Pharma for Bertilimumab 24

iCo Therapeutics Exercises Option Licensing Agreement With Immune Pharma For Bertilimumab 25

Immune Pharma to Spin-off its Cytovia 26

Immune Pharma Plans to Raise up to USD3 Million in Public Offering of Shares 27

Immune Pharma Completes Spin Off of Pain and Neurology Business 28

Maxim Pharma to Raise upto USD20 Million in Private Placement of Shares 29

Immune Pharma to Raise USD2 Million in Share Purchase Plan 29

Immune Pharma to Raise USD1 Million in Private Placement of Shares 30

Immune Pharma to Raise up to USD2.2 Million in Private Placement of Shares 31

Immune Pharma to Raise up to USD1.5 Million in Private Placement of Shares 33

Immune Pharmaceuticals Raises USD9 Million in Private Placement of Series D Redeemable Convertible Preferred Stock 34

Immune Pharma Completes Underwriters Exercise of Partial Over-Allotment Option of Public Offering of Units for USD9.7 Million 35

Immune Pharma Raises USD1 Million in Private Placement of Units 36

Immune Pharma Announces Private Placement Of Securities For US$11.7 Million 37

Immune Pharma Raises USD1 Million in Private Placement of Convertible Notes 38

Immune Pharma Completes Acquisition Of EpiCept In Reverse Takeover Transaction 38

Immune Pharmaceuticals Inc, Key Competitors 41

Immune Pharmaceuticals Inc, Key Employees 42

Immune Pharmaceuticals Inc, Other Locations 43

Immune Pharmaceuticals Inc, Subsidiaries 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Immune Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16120
Site License
USD 500 INR 32240
Corporate User License
USD 750 INR 48360

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com